Efficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatments

Simple item page
dc.contributor.buuauthorTaş, Aytul
dc.contributor.buuauthorErsoy, Alparslan
dc.contributor.buuauthorErsoy, Canan
dc.contributor.buuauthorGüllülü, Mustafa
dc.contributor.buuauthorYutkuran, Mustafa
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.contributor.researcheridAAH-8861-2021tr_TR
dc.contributor.scopusid7005413890tr_TR
dc.contributor.scopusid35612977100tr_TR
dc.contributor.scopusid6701485882tr_TR
dc.contributor.scopusid6602684544tr_TR
dc.contributor.scopusid7003389525tr_TR
dc.date.accessioned2021-12-03T08:19:19Z
dc.date.available2021-12-03T08:19:19Z
dc.date.issued2006
dc.description.abstractThe aim of this study was to evaluate the effects of recombinant human erythropoietin (Epo), testosterone ( T) or a combination of them in the treatment of erectile dysfunction (ED) in hemodialysis patients, as well as the efficacy of sildenafil in patients unresponsive to combination treatment. A total of 23 patients with ED were divided into two groups. The international index of erectile function (IIEF) was used to evaluate ED and treatment response. Patients received Epo or T treatments for 12 weeks. Later on both groups received combination treatment for another 12 weeks. Although IIEF scores increased significantly in both groups after the combination treatment, the score changes were similar. After combination treatment, 16 patients still having IIEF score <26 were given sildenafil treatment in combination with Epo while T was discontinued. Although the IIEF scores increased significantly in all patients (17.4%), only eight of them attained an IIEF score of >= 26. The baseline IIEF scores of the patients with satisfactory response to the sildenafil treatment were higher than those with unsatisfactory response. The patients with a score of >= 22 responded better to the treatment. Although Epo and/or T therapies could partially improve ED in male dialysis patients besides correcting renal anemia and hypogonadism, sildenafil treatment could improve ED in unresponsive patients. Especially, those with higher baseline IIEF scores benefited more.en_US
dc.identifier.citationTaş, A. vd. (2006). ''Efficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatments''. International Journal of Impotence Research, 18(1), 61-68.en_US
dc.identifier.endpage68tr_TR
dc.identifier.issn0955-9930
dc.identifier.issn1476-5489
dc.identifier.issue1tr_TR
dc.identifier.pubmed16177828tr_TR
dc.identifier.scopus2-s2.0-30044432896tr_TR
dc.identifier.startpage61tr_TR
dc.identifier.urihttps://doi.org/10.1038/sj.ijir.3901372
dc.identifier.urihttps://www.nature.com/articles/3901372
dc.identifier.urihttp://hdl.handle.net/11452/22983
dc.identifier.volume18tr_TR
dc.identifier.wos000236468400010tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.journalInternational Journal of Impotence Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectUrology & nephrologyen_US
dc.subjectTestosteroneen_US
dc.subjectSildenafilen_US
dc.subjectIIEF scoringen_US
dc.subjectHemodialysisen_US
dc.subjectErythropoietinen_US
dc.subjectErectile dysfunctionen_US
dc.subjectViagraen_US
dc.subjectSustanonen_US
dc.subjectQualityen_US
dc.subjectProlactinen_US
dc.subjectAssociationen_US
dc.subjectImpotenceen_US
dc.subjectTherapyen_US
dc.subjectRenal-failureen_US
dc.subjectOral sildenafilen_US
dc.subjectSexual dysfunctionen_US
dc.subjectMale hemodialysis-patientsen_US
dc.subjectRecombinant-human-erythropoietinen_US
dc.subject.emtreeTestosteroneen_US
dc.subject.emtreeSildenafilen_US
dc.subject.emtreeErythropoietinen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeScoring systemen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreePatient satisfactionen_US
dc.subject.emtreePatienten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHemodialysisen_US
dc.subject.emtreeEvaluationen_US
dc.subject.emtreeErectile dysfunctionen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAnemiaen_US
dc.subject.meshTestosteroneen_US
dc.subject.meshRenal dialysisen_US
dc.subject.meshQuestionnairesen_US
dc.subject.meshPiperazinesen_US
dc.subject.meshMaleen_US
dc.subject.meshImpotenceen_US
dc.subject.meshHumansen_US
dc.subject.meshErythropoietinen_US
dc.subject.meshBody mass indexen_US
dc.subject.meshBlood pressureen_US
dc.subject.meshAdulten_US
dc.subject.scopusImpotence; Kidney Transplantation; Chronic Kidney Failureen_US
dc.subject.wosUrology & nephrologyen_US
dc.titleEfficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatmentsen_US
dc.typeArticle
dc.wos.quartileQ2en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
3901372.pdf
Size:
166.65 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus